30 related articles for article (PubMed ID: 10367679)
1. Preclinical studies in rats and squirrel monkeys for safety evaluation of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1).
Woo JH; Bour SH; Dang T; Lee YJ; Park SK; Andreas E; Kang SH; Liu JS; Neville DM; Frankel AE
Cancer Immunol Immunother; 2008 Aug; 57(8):1225-39. PubMed ID: 18256829
[TBL] [Abstract][Full Text] [Related]
2. Targeted Fc2'-3-PE40 chimeric protein abolishes passive cutaneous anaphylaxis in mice.
Fishman A; Prus D; Belostotsky R; Lorberboum-Galski H
Clin Exp Immunol; 2000 Mar; 119(3):398-403. PubMed ID: 10691909
[TBL] [Abstract][Full Text] [Related]
3. Recombinant Immunotoxin 4D5scFv-PE40 for Targeted Therapy of HER2-Positive Tumors.
Sokolova EA; Stremovskiy OA; Zdobnova TA; Balalaeva IV; Deyev SM
Acta Naturae; 2015; 7(4):93-6. PubMed ID: 26798495
[TBL] [Abstract][Full Text] [Related]
4. Intraperitoneal administration of gonadotropin-releasing hormone-PE40 induces castration in male rats.
Yu L; Zhang ZF; Jing CX; Wu FL
World J Gastroenterol; 2008 Apr; 14(13):2106-9. PubMed ID: 18395915
[TBL] [Abstract][Full Text] [Related]
5. Immunological hormone atrophy by gonadotropin-based drug.
Li J; Zhang J
Int J Exp Pathol; 2006 Dec; 87(6):495-9. PubMed ID: 17222217
[TBL] [Abstract][Full Text] [Related]
6. Immunotoxins for targeted cancer therapy.
Kreitman RJ
AAPS J; 2006 Aug; 8(3):E532-51. PubMed ID: 17025272
[TBL] [Abstract][Full Text] [Related]
7. Ability of luteinizing hormone releasing hormone-Pseudomonas aeruginosa exotoxin 40 binding to LHRH receptor on human liver cancer cells.
Gong SL; Zhao G; Zhao HG; Lu WT; Liu GW; Zhu P
World J Gastroenterol; 2004 Oct; 10(19):2870-3. PubMed ID: 15334689
[TBL] [Abstract][Full Text] [Related]
8. Designing immunotoxins for cancer therapy.
Pennell CA; Erickson HA
Immunol Res; 2002; 25(2):177-91. PubMed ID: 11999171
[TBL] [Abstract][Full Text] [Related]
9. Single-chain fusion toxins for the treatment of breast cancer: antitumor activity of BR96 sFv-PE40 and heregulin-PE40.
Siegall CB
Recent Results Cancer Res; 1996; 140():51-60. PubMed ID: 8787077
[No Abstract] [Full Text] [Related]
10. BR96 sFv-PE40 immunotoxin: nonclinical safety assessment.
Haggerty HG; Warner WA; Comereski CR; Peden WM; Mezza LE; Damle BD; Siegall CB; Davidson TJ
Toxicol Pathol; 1999; 27(1):87-94. PubMed ID: 10367679
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of the single-chain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenografts.
Friedman PN; Chace DF; Trail PA; Siegall CB
J Immunol; 1993 Apr; 150(7):3054-61. PubMed ID: 8454873
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo characterization of BR96 sFv-PE40. A single-chain immunotoxin fusion protein that cures human breast carcinoma xenografts in athymic mice and rats.
Siegall CB; Chace D; Mixan B; Garrigues U; Wan H; Paul L; Wolff E; Hellström I; Hellström KE
J Immunol; 1994 Mar; 152(5):2377-84. PubMed ID: 8133048
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy of carcinomas using BR96 sFv-PE40, a single-chain immunotoxin that binds to the Le(y) antigen.
Siegall CB
Semin Cancer Biol; 1995 Oct; 6(5):289-95. PubMed ID: 8562906
[TBL] [Abstract][Full Text] [Related]
14. BR96 sFv-PE40, a potent single-chain immunotoxin that selectively kills carcinoma cells.
Friedman PN; McAndrew SJ; Gawlak SL; Chace D; Trail PA; Brown JP; Siegall CB
Cancer Res; 1993 Jan; 53(2):334-9. PubMed ID: 8417827
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]